AbbVie Expands US AI Manufacturing As Risankizumab Trial Supports Valuation Gap
AbbVie (NYSE:ABBV) plans to invest US$380 million in two new US active pharmaceutical ingredient manufacturing facilities that will use artificial int...
Neutral
1.0